{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:33:54Z","timestamp":1740180834351,"version":"3.37.3"},"reference-count":37,"publisher":"Consilium Medicum","issue":"3","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Pulmonary hypertension (PH) is a progressive disease which is characterized with the increase of pulmonary artery pressure and pulmonary vascular resistance. Such condition leads to right ventricular heart failure and premature death of patients. Pulmonary arterial hypertension (PAH) has the status of an orphan disease. However in Russia only idiopathic PH is included in the list of 24 life-threatening and chronic progressive rare diseases, while other forms of PH are not in it. Inclusion in this list guarantees drug provision for patients at the expense of the regional budget, while patients with other forms of PH can rely on free medication only if they have a disability. The lack of criteria for revising this list as well as the imperfection of legal regulation in the field of drug support for orphan diseases leads to high disability, a significant decrease in the duration and quality of life of patients with PH. As part of a multicriteria approach, a clinical and economic analysis of the disease burden can be one of the tools for policy development and decision-making on the distribution of funding in the healthcare. The article provides a review of the economic burden of various forms of PH in the world.<\/jats:p>","DOI":"10.26442\/00403660.2020.03.000591","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T14:35:20Z","timestamp":1593441320000},"page":"125-131","source":"Crossref","is-referenced-by-count":0,"title":["Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world"],"prefix":"10.26442","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-3727","authenticated-orcid":false,"given":"V. D.","family":"Zakiev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9842","authenticated-orcid":false,"given":"A. D.","family":"Gvozdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-8097","authenticated-orcid":false,"given":"T. V.","family":"Martynyuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"ref2","unstructured":"\u0427\u0430\u0437\u043e\u0432\u0430 \u0418.\u0415., \u0410\u0432\u0434\u0435\u0435\u0432 \u0421.\u041d., \u0426\u0430\u0440\u0435\u0432\u0430 \u041d.\u0410. \u0438 \u0434\u0440. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u043b\u0435\u0433\u043e\u0447\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u043e\u043d\u0438\u0438. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2014;86(9):4-23 [Chazova IE, Avdeev SN, Tsareva NA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Therapeutic Archive. 2014;86(9):4-23 (In Russ.)]."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.26442\/2075-082X_14.3.58-64"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18093\/0869-0189-2017-27-6-803-810"},{"key":"ref5","unstructured":"\u041f\u043e\u0441\u0442\u0430\u043d\u043e\u0432\u043b\u0435\u043d\u0438\u0435 \u041f\u0440\u0430\u0432\u0438\u0442\u0435\u043b\u044c\u0441\u0442\u0432\u0430 \u0420\u0424 \u043e\u0442 26.04.2012 \u2116403 (\u0440\u0435\u0434. \u043e\u0442 20.11.2018) \u00ab\u041e \u043f\u043e\u0440\u044f\u0434\u043a\u0435 \u0432\u0435\u0434\u0435\u043d\u0438\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0430 \u043b\u0438\u0446, \u0441\u0442\u0440\u0430\u0434\u0430\u044e\u0449\u0438\u0445 \u0436\u0438\u0437\u043d\u0435\u0443\u0433\u0440\u043e\u0436\u0430\u044e\u0449\u0438\u043c\u0438 \u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c\u0438 \u043f\u0440\u043e\u0433\u0440\u0435\u0441\u0441\u0438\u0440\u0443\u044e\u0449\u0438\u043c\u0438 \u0440\u0435\u0434\u043a\u0438\u043c\u0438 (\u043e\u0440\u0444\u0430\u043d\u043d\u044b\u043c\u0438) \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f\u043c\u0438, \u043f\u0440\u0438\u0432\u043e\u0434\u044f\u0449\u0438\u043c\u0438 \u043a \u0441\u043e\u043a\u0440\u0430\u0449\u0435\u043d\u0438\u044e \u043f\u0440\u043e\u0434\u043e\u043b\u0436\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u0441\u0442\u0438 \u0436\u0438\u0437\u043d\u0438 \u0433\u0440\u0430\u0436\u0434\u0430\u043d \u0438\u043b\u0438 \u0438\u0445 \u0438\u043d\u0432\u0430\u043b\u0438\u0434\u043d\u043e\u0441\u0442\u0438, \u0438 \u0435\u0433\u043e \u0440\u0435\u0433\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u0441\u0435\u0433\u043c\u0435\u043d\u0442\u0430\u00bb [Decree of the Government of the Russian Federation from April 26, 2012 No. 403 (as amended on November 20, 2018) \u201cOn the Procedure for Maintaining the Federal Register of Persons Suffering Life-threatening and Chronic Progressing Rare (Orphan) Diseases, Leading to a Reduction in the Life Duration of Citizens or Their Disability, and Its Regional segment\u201c (In Russ.)]."},{"key":"ref6","unstructured":"\u0418\u0433\u043d\u0430\u0442\u044c\u0435\u0432\u0430 \u0412.\u0418., \u0410\u0432\u043a\u0441\u0435\u043d\u0442\u044c\u0435\u0432\u0430 \u041c.\u0412. \u0410\u043d\u0430\u043b\u0438\u0437 \u043c\u0435\u0442\u043e\u0434\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u043e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0435\u0439 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0439 \u043f\u043e \u0438\u0437\u0443\u0447\u0435\u043d\u0438\u044e \u0441\u043e\u0446\u0438\u0430\u043b\u044c\u043d\u043e-\u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0431\u0440\u0435\u043c\u0435\u043d\u0438 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439 \u0432 \u0420\u0424 \u0432 \u0440\u0430\u043c\u043a\u0430\u0445 \u0440\u0430\u0437\u0440\u0430\u0431\u043e\u0442\u043a\u0438 \u0441\u0442\u0430\u043d\u0434\u0430\u0440\u0442\u043d\u043e\u0439 \u043c\u0435\u0442\u043e\u0434\u0438\u043a\u0438 \u0430\u043d\u0430\u043b\u0438\u0437\u0430 \u0441\u0442\u043e\u0438\u043c\u043e\u0441\u0442\u0438 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u0441 \u0446\u0435\u043b\u044c\u044e \u0435\u0435 \u0438\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043d\u0438\u044f \u0432 \u043e\u0446\u0435\u043d\u043a\u0435 \u0442\u0435\u0445\u043d\u043e\u043b\u043e\u0433\u0438\u0439 \u0437\u0434\u0440\u0430\u0432\u043e\u043e\u0445\u0440\u0430\u043d\u0435\u043d\u0438\u044f. \u0424\u0430\u0440\u043c\u0430\u043a\u043e\u044d\u043a\u043e\u043d\u043e\u043c\u0438\u043a\u0430. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u044d\u043a\u043e\u043d\u043e\u043c\u0438\u043a\u0430 \u0438 \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u044d\u043f\u0438\u0434\u0435\u043c\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2014;7(3) [Ignatieva VI, Avksentieva MV. An analysis of the methodological features of research on the socio-economic burden of disease in the Russian Federation as part of the development of a standard methodology for analyzing the cost of a disease with a view to its use in assessing healthcare technologies. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2014;7(3) (In Russ.)]."},{"key":"ref7","unstructured":"\u041e\u0441\u043d\u043e\u0432\u043d\u044b\u0435 \u043f\u043e\u043d\u044f\u0442\u0438\u044f \u0432 \u043e\u0446\u0435\u043d\u043a\u0435 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0445 \u0442\u0435\u0445\u043d\u043e\u043b\u043e\u0433\u0438\u0439. \u041c\u0435\u0442\u043e\u0434\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u043f\u043e\u0441\u043e\u0431\u0438\u0435. \u041f\u043e\u0434 \u043e\u0431\u0449. \u0440\u0435\u0434. \u0410.\u0421. \u041a\u043e\u043b\u0431\u0438\u043d\u0430, \u0421.\u041a. \u0417\u044b\u0440\u044f\u043d\u043e\u0432\u0430, \u0414.\u042e. \u0411\u0435\u043b\u043e\u0443\u0441\u043e\u0432\u0430. \u041c.: \u041e\u041a\u0418, 2013 [Basic concepts of medical technology evaluation. Toolkit. Ed. A.S. Kolbina, S.K. Zyryanova, D.Yu. Belousova. Moscow: OKI, 2013 (In Russ.)]."},{"key":"ref8","unstructured":"\u0425\u0430\u0431\u0440\u0438\u0435\u0432 \u0420.\u0423., \u042f\u0433\u0443\u0434\u0438\u043d\u0430 \u0420.\u0418., \u041f\u0440\u0430\u0432\u0434\u044e\u043a \u041d.\u0413. \u041e\u0446\u0435\u043d\u043a\u0430 \u0442\u0435\u0445\u043d\u043e\u043b\u043e\u0433\u0438\u0439 \u0437\u0434\u0440\u0430\u0432\u043e\u043e\u0445\u0440\u0430\u043d\u0435\u043d\u0438\u044f. \u041c.: \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u043e\u0435 \u0438\u043d\u0444\u043e\u0440\u043c\u0430\u0446\u0438\u043e\u043d\u043d\u043e\u0435 \u0430\u0433\u0435\u043d\u0442\u0441\u0442\u0432\u043e, 2013 [Khabriev RU, Yagudina RI, Pravdyuk NG. Health technology assessment. Moscow: Medical News Agency, 2013 (In Russ.)]."},{"key":"ref9","unstructured":"\u041e\u0446\u0435\u043d\u043a\u0430 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0445 \u0442\u0435\u0445\u043d\u043e\u043b\u043e\u0433\u0438\u0439. \u041c\u0435\u0436\u0434\u0443\u043d\u0430\u0440\u043e\u0434\u043d\u044b\u0439 \u043e\u043f\u044b\u0442. \u041f\u043e\u0434 \u0440\u0435\u0434. \u0412.\u0418. \u0421\u0442\u0430\u0440\u043e\u0434\u0443\u0431\u043e\u0432\u0430, \u0418.\u041d. \u041a\u0430\u0433\u0440\u0430\u043c\u0430\u043d\u044f\u043d\u0430. \u041c., 2012 [Assessment of medical technology. International experience. Ed. V.I. Starodubova, I.N. Kahramanyan. Moscow, 2012 (In Russ.)]."},{"key":"ref10","unstructured":"\u041e\u043c\u0435\u043b\u044c\u044f\u043d\u043e\u0432\u0441\u043a\u0438\u0439 \u0412.\u0412., \u0410\u0432\u043a\u0441\u0435\u043d\u0442\u044c\u0435\u0432\u0430 \u041c.\u0412., \u0414\u0435\u0440\u043a\u0430\u0447 \u0415.\u0412. \u0438 \u0434\u0440. \u0410\u043d\u0430\u043b\u0438\u0437 \u0441\u0442\u043e\u0438\u043c\u043e\u0441\u0442\u0438 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u2013 \u043f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u0438 \u043f\u0443\u0442\u0438 \u0440\u0435\u0448\u0435\u043d\u0438\u044f. \u041f\u0435\u0434\u0438\u0430\u0442\u0440\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u043b\u043e\u0433\u0438\u044f. 2011;3:6-12 [Omel\u2019yanovskii VV, Avksent\u2019eva MV, Derkach EV, et al. Analysis of the cost of the disease \u2013 problems and solutions. Pediatric pharmacology. 2011;8(3):6-12 (In Russ.)]."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.30809\/phe.2.2016.8"},{"key":"ref12","unstructured":"\u041c\u0435\u0442\u043e\u0434\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0440\u0430\u0441\u0447\u0435\u0442\u0443 \u0437\u0430\u0442\u0440\u0430\u0442 \u043f\u0440\u0438 \u043f\u0440\u043e\u0432\u0435\u0434\u0435\u043d\u0438\u0438 \u043a\u043b\u0438\u043d\u0438\u043a\u043e-\u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0439 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432. \u041c.: \u0424\u0413\u0411\u0423 \u0426\u042d\u041a\u041a\u041c\u041f, 2018 [Guidelines for calculating costs in conducting clinical and economic studies of drugs. Moscow: FGBU CEKKMP, 2018 (In Russ.)]. https:\/\/rosmedex.ru\/wp-content\/uploads\/2019\/06\/MR-AVB_novaya-redaktsiya_2018-g..pdf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.30809\/phe.3.2016.4"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Burger CD, Ghandour M, Padmanabhan Menon D, et al. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;9:731-9.","DOI":"10.2147\/CEOR.S119117"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improved functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108(17):2066-9.","DOI":"10.1161\/01.CIR.0000099502.17776.C2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24(6):1007-10.","DOI":"10.1183\/09031936.04.00051104"},{"key":"ref17","unstructured":"Burke JP, Hunsche E, Regulier E, et al. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Am J Manag Care. 2015;21(3 Suppl.):s47-s58."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/11592430-000000000-00000"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Said Q, Martin BC, Joish VN, et al. The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15:500-8.","DOI":"10.3111\/13696998.2012.665109"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.496694"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0361-0"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Copher R, Cerulli A, Watkins A, Laura MM. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ. 2012;15:947-55.","DOI":"10.3111\/13696998.2012.690801"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676.","DOI":"10.1186\/s12913-014-0676-0"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.17391"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/2045894018816294"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1363049"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.03.950"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med. 2010;104:902-10.","DOI":"10.1016\/j.rmed.2010.01.002"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a U.S. privately insured population. Appl Health Econ Health Policy. 2011;9(6):377-87.","DOI":"10.2165\/11592440-000000000-00000"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.26442\/terarkh2018909101-109"},{"key":"ref31","unstructured":"UK National Specialised Commissioning Team. Service Specification 2011\/2012."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-246"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1821901"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Heresi GA, Platt DM, Wang W, et al. Healthcare burden of pulmonary hypertension owing to lung disease and\/or hypoxia. BMC Pulm Med. 2017;17(1):58.","DOI":"10.1186\/s12890-017-0399-1"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.14341\/DM9278"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"\u041a\u043e\u043d\u0446\u0435\u0432\u0430\u044f \u0410.\u0412, \u041a\u0430\u043b\u0438\u043d\u0438\u043d\u0430 \u0410.\u041c., \u041a\u043e\u043b\u0442\u0443\u043d\u043e\u0432 \u0418.\u0415., \u041e\u0433\u0430\u043d\u043e\u0432 \u0420.\u0413. \u0421\u043e\u0446\u0438\u0430\u043b\u044c\u043d\u043e-\u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0443\u0449\u0435\u0440\u0431 \u043e\u0442 \u043e\u0441\u0442\u0440\u043e\u0433\u043e \u043a\u043e\u0440\u043e\u043d\u0430\u0440\u043d\u043e\u0433\u043e \u0441\u0438\u043d\u0434\u0440\u043e\u043c\u0430 \u0432 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438. \u0420\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u0442\u0435\u0440\u0430\u043f\u0438\u044f \u0432 \u043a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u0438\u0438. 2011;7(2):158-66 [Kontsevaya AV, Kalinina AM, Koltunov IE, Oganov RG. Socio-economic damage from acute coronary syndrome in the Russian Federation. State Research Center for Preventive Medicine. Rational pharmacotherapy in cardiology. 2011;7(2):158-66 (In Russ.)].","DOI":"10.20996\/1819-6446-2011-7-2-158-166"},{"key":"ref37","unstructured":"\u041a\u043e\u043b\u0431\u0438\u043d \u0410.\u0421., \u0422\u0430\u0442\u0430\u0440\u0441\u043a\u0438\u0439 \u0411.\u0410., \u0411\u0438\u0441\u0435\u0440\u043e\u0432\u0430 \u0418.\u041d. \u0438 \u0434\u0440. \u0421\u043e\u0446\u0438\u0430\u043b\u044c\u043d\u043e-\u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u0431\u0440\u0435\u043c\u044f \u043c\u0435\u0440\u0446\u0430\u0442\u0435\u043b\u044c\u043d\u043e\u0439 \u0430\u0440\u0438\u0442\u043c\u0438\u0438 \u0432 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f. 2010;19(4):17-22 [Kolbin AS, Tatarsky BA, Biserova IN, et al. Socio-economic burden of atrial fibrillation in the Russian Federation. Clinical pharmacology and therapy. 2010;19(4):17-22 (In Russ.)]."}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33925\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33925\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:53:26Z","timestamp":1634158406000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,27]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2020.03.000591","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2020,3,27]]}}}